Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Imbruvica | ibrutinib | Chronic lymphocytic leukemia (CLL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Venclexta | Venetoclax | Chronic Lymphocytic Leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zydelig | Idelalisib | Chronic lymphocytic leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Arzerra | Ofatumumab | Chronic Lymphocytic Leukemia | Do not reimburse | Complete | ||
| Gazyva | Obinutuzumab | Chronic Lymphocytic Leukemia | Reimburse | Complete | ||
| Treanda (in combination with rituximab) | Bendamustine hydrochloride | Chronic Lymphocytic Leukemia | Withdrawn | |||
| Forxiga | dapagliflozin | Chronic kidney disease | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| N/A | dapagliflozin | Chronic kidney disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Korsuva | difelikefalin | Chronic kidney disease | Do not reimburse | Complete | ||
| Kerendia | finerenone | Chronic kidney disease | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 9, 2024